Court rejects Healthscope
Tuesday, 02 September, 2008
The NSW Supreme Court has rejected Healthscope's [ASX: HSP] appeal for a break free from Symbion Health.
Healthscope, a private hospital operator which also owns some pathology businesses, had argued that pathology specialist Symbion should pay the company $19.5 million after reneging on a deal which would have seen Healthscope acquire Symbion's diagnostics business.
The court ordered that the break fee was not required. Healthscope is planning to lodge an appeal with the NSW Court of Appeal.
Multiple myeloma treatment reprograms patients' own immune cells
An Australian and Victorian Government funding agreement has allowed eligible Australians with...
Could 'fusion proteins' reduce errors in a promising gene-editing tool?
Gene-editing tool CRISPR-Cas9 is used, among many things, to engineer new cancer immunotherapies....
Cancer research and clinical trials at the core of new centre
The Australian Cancer Research Foundation Centre for Dynamic Immuno-Oncology (CDIO) has been...
